Lifecore Biomedical, Inc. (NASDAQ:LFCR) Stock Holdings Decreased by BNP Paribas Financial Markets

BNP Paribas Financial Markets lowered its stake in Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 72.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 14,966 shares of the company’s stock after selling 39,433 shares during the period. BNP Paribas Financial Markets’ holdings in Lifecore Biomedical were worth $111,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Steward Partners Investment Advisory LLC boosted its holdings in shares of Lifecore Biomedical by 61.2% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 27,184 shares of the company’s stock valued at $202,000 after buying an additional 10,320 shares during the period. Northern Trust Corp boosted its holdings in shares of Lifecore Biomedical by 14.5% in the 4th quarter. Northern Trust Corp now owns 221,498 shares of the company’s stock valued at $1,646,000 after buying an additional 28,019 shares during the period. Bank of New York Mellon Corp boosted its holdings in shares of Lifecore Biomedical by 71.9% in the 4th quarter. Bank of New York Mellon Corp now owns 80,572 shares of the company’s stock valued at $599,000 after buying an additional 33,690 shares during the period. Barclays PLC boosted its holdings in shares of Lifecore Biomedical by 13.5% in the 4th quarter. Barclays PLC now owns 33,972 shares of the company’s stock valued at $253,000 after buying an additional 4,028 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Lifecore Biomedical by 125.9% in the 4th quarter. Rhumbline Advisers now owns 55,723 shares of the company’s stock valued at $414,000 after buying an additional 31,056 shares during the period. Institutional investors own 83.36% of the company’s stock.

Wall Street Analyst Weigh In

Separately, William Blair initiated coverage on shares of Lifecore Biomedical in a report on Wednesday, May 21st. They issued an “outperform” rating for the company.

Insider Buying and Selling at Lifecore Biomedical

In other Lifecore Biomedical news, major shareholder Aron R. English sold 150,419 shares of the business’s stock in a transaction dated Wednesday, May 28th. The shares were sold at an average price of $7.12, for a total transaction of $1,070,983.28. Following the completion of the transaction, the insider now directly owns 264,180 shares of the company’s stock, valued at $1,880,961.60. The trade was a 36.28% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold 1,485,182 shares of company stock valued at $9,824,031 in the last ninety days. Company insiders own 32.20% of the company’s stock.

Lifecore Biomedical Trading Down 3.5%

NASDAQ LFCR opened at $6.61 on Friday. Lifecore Biomedical, Inc. has a one year low of $3.68 and a one year high of $7.99. The company has a 50-day simple moving average of $6.52 and a 200-day simple moving average of $6.57. The company has a debt-to-equity ratio of 9.21, a quick ratio of 1.21 and a current ratio of 2.32. The firm has a market capitalization of $244.74 million, a PE ratio of -11.80 and a beta of 0.65.

Lifecore Biomedical (NASDAQ:LFCR) last posted its earnings results on Thursday, April 3rd. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $35.15 million for the quarter, compared to analyst estimates of $33.23 million. Lifecore Biomedical had a negative net margin of 12.52% and a negative return on equity of 315.23%. On average, equities analysts forecast that Lifecore Biomedical, Inc. will post -0.91 earnings per share for the current year.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.